AA
RGLS

ALPS Advisors’s Regulus Therapeutics RGLS Stock Holding History

ALPS Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-561
Closed -$222K – 729
2016
Q3 		$222K Sell
561
-57
-9% -$23.4K ﹤0.01% 653
2016
Q2 		$214K Buy
618
+124
+25% +$88.8K ﹤0.01% 599
2016
Q1 		$411K Sell
494
-81
-14% -$64.4K ﹤0.01% 546
2015
Q4 		$601K Buy
+575
New +$576K 0.01% 273

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

ALPS Advisors's RGLS Position: Q4 2016 in Review

ALPS Advisors sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 561 shares — an estimated $222K sold.

ALPS Advisors first reported a position in RGLS in Q4 2015 and held it in 4 quarters. The position peaked at $601K in Q4 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • ALPS Advisors reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • ALPS Advisors sold 561 Regulus Therapeutics shares in Q4 2016, an estimated $222K.
  • ALPS Advisors first reported a position in Regulus Therapeutics in Q4 2015 and held it in 4 quarters.
  • ALPS Advisors's Regulus Therapeutics position peaked at $601K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on ALPS Advisors's 13F filing for Q4 2016, filed 24 Jan 2017.